C3 Jian has successfully completed a phase I clinical trial for its C16G2 caries-fighting peptide drug.
The randomized, double-blind, placebo-controlled trial included a dose-escalation period, the company explained in a press release. The trial focused on evaluating safety and pharmacokinetics, along with the initial microbiology of C16G2 administered to healthy adults in a single oral dose of mouth rinse. A total of 36 subjects were enrolled in the study. No C16G2-related events and no severe or serious adverse events were reported in the study.
The trial was conducted at New York University's Bluestone Center for Clinical Research.
